Summary
Entegris, Inc. reported a net loss of $16.1 million ($0.12 per share) for the quarter ended November 26, 2005, a significant decline from a net income of $5.7 million ($0.08 per share) in the prior year's comparable quarter. This loss was primarily driven by the inclusion of Mykrolis Corporation's results following their merger in August 2005, which contributed $64.7 million in sales but also resulted in substantial integration costs, higher operating expenses, and a significant charge-off of acquired inventory ($17.8 million). The company is actively divesting non-core product lines, including life science, tape and reel, and gas delivery businesses, which are being classified as discontinued operations. Despite the reported net loss, the company's balance sheet remains solid with $274.8 million in cash, cash equivalents, and short-term investments. However, operational performance was impacted by lower gross margins (32.5% vs. 42.2%) due to the aforementioned inventory write-up and restructuring costs, as well as increased selling, general, and administrative expenses (38.5% of sales vs. 26.8%). The company is undertaking restructuring efforts and expects to realize cost synergies from the Mykrolis merger by mid-calendar 2006, which should improve future profitability.
Key Highlights
- 1Reported a net loss of $16.1 million for the quarter, compared to a net income of $5.7 million in the prior year.
- 2Net sales increased 65% year-over-year to $146.8 million, largely due to the acquisition of Mykrolis Corporation.
- 3Gross margin decreased significantly to 32.5% from 42.2% in the prior year, impacted by a $17.8 million inventory write-up and restructuring costs.
- 4Selling, general, and administrative expenses increased substantially by 136% due to merger integration costs and Mykrolis's operating expenses.
- 5The company is divesting three product lines (gas delivery, life science, tape and reel) classified as discontinued operations.
- 6Cash, cash equivalents, and short-term investments remained strong at $274.8 million.
- 7Restructuring and integration costs related to the Mykrolis merger are expected to continue through mid-2006, with annualized cost savings anticipated by then.